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vs. 7% (range: 0% (Germany/Spain) -25% (UK)). Latest disease severity measures 
documented were (adalimumab vs. etanercept): Swollen Joint Counts: 1.6 (range: 
0.4 (Spain) -2.9 (UK)) vs. 2.7 (1.4 (Germany) -8.0 (UK)), Tender Joint Counts: 2.4 
(range: 0.9 (Spain) -3.5 (Italy)) vs. 4.1 (range: 1.9 (Germany) -9.8 (UK)), and HAQ 
rating: 1.2 (range: 0.4 (Spain) -2.7 (Germany)) vs. 1.5 (range: 1.3 (Germany) -2.0 
(France)). ConClusions: Among PsA patients receiving adalimumab or etaner-
cept monotherapy, disease severity differed within the EU5, with patients on 
etanercept, and patients in Italy and UK, having relatively higher burden and 
poorer outcomes. Factors influencing the observed patterns of geographic varia-
tion and the impact of specific biologic treatments on observed patterns warrant 
further scrutiny to optimize therapeutic interventions and improve outcomes.
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objeCtives: Assess the relative efficacy and safety of ustekinumab compared 
to reimbursed anti-TNF-alfa therapies in patients with active psoriatic arthritis 
(PsA). Methods: Randomized, placebo-controlled, at least 24-week-long, pivotal 
studies were searched in PubMed and EMBASE databases. Patients, participating 
in these trials, had active psoriatic arthritis. They were treated with DMARD and/
or NSAID therapies and had not received any biological treatment before. Meta-
analysis was based on ACR20, ACR50, ACR70, PASI75, HAQ-DI, AE and SAE endpoints. 
The quality assessment of evidences was based on EUnetHTA guidelines. For the 
applicability evaluation Aetkin’s method was used, while the meta-analysis used 
Frequentist approach. The mean and the 95% confidence interval of odd ratios (OR) 
were estimated with the Mantel-Haenszel test and with the fixed effect method. 
Statistical heterogeneity was tested using the Chi-squared-test, publication bias 
was checked with funnel plot. Results: During the literature search 8 studies were 
identified. One study was excluded from the evaluation due to inadequate treatment 
dose. Due to altering placebo arm treatment and a high risk of bias at study level, two 
studies were involved in sensitivity analyses. Anti-TNF-alfa treatments had signifi-
cantly better results on primary and accentuated secondary endpoints (ACR20 week 
24 - ustekinumab vs. placebo: OR= 2,56 (95%CI= 1,74; 3,74); anti-TNF-alfa vs. placebo: 
OR= 7,89 (95%CI= 5,65; 11,1); ACR50 week 24 – ustekinumab vs. placebo: OR= 3,46 
(95%CI= 1,94; 6,17); anti-TNF-alfa vs. placebo: OR= 14,21 (95%CI= 8,01; 25,23)). On the 
other secondary endpoints the differences were not significant, however results 
have shown subservient tendency for anti-TNF-alfa treatment against ustekinumab. 
During the safety comparisons we did not find a substantial difference between 
these treatments. ConClusions: Based on our evaluation the anti-TNF-alfa treat-
ment appears more effective than ustekinumab in the first line biologic treatment 
of psoriatic arthritis.
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objeCtives: To prevent irreversible joint damage in rheumatoid arthritis (RA), bio-
logical drugs have been developed; when insufficient response is observed, the ini-
tial dosage could be increased (dose escalation). The aim of the study was to assess 
dose escalation among different therapeutic strategies and associated health care 
resources use. Methods: An observational retrospective cohort analysis based 
on 3 Local Health Units administrative databases was conducted. Patients who 
filled at least one prescription for biologic agents with a diagnosis of RA between 
01/01/2009-31/12/2011 (enrolment period) were included. Patients were followed-
up for 12 months and characterized on the basis of the previous 12 months. Dose 
escalation and cost of illness were calculated on naïve patients (patients with no 
prior prescriptions of the index biologic); dose escalation was defined as having ≥ 2 
consecutive claims with an average weekly dose 130% greater than the initial aver-
age weekly dose. Results: 594 patients were analyzed, female: male ratio= 3: 1, age 
54±14. Biologic at index date were Etanercept (39%), Adalimumab (25%), Infliximab 
(14%), Abatacept (10%), Tocilizumab (9%), Golimumab (3%). Naïve patients to index 
biologic were 293 (49%); among them, dose escalation was observed in 21.4% 
patients on Infliximab, 11.5% Adalimumab, 5.6% Abatacept, 4.0% Tocilizumab, 3.8% 
Etanercept. Hospitalized patients with RA as main discharge diagnosis were 9.6% 
Infliximab, 6.7% Golimumab, 6.6% Adalimumab, 2.9% Tocilizumab, 2.8% Etanercept, 
2.4% Abatacept. Overall, 95% of cost of illness was driven by biologics, 2% tradi-
tional DMARDs, 3% non pharmacological costs; annual cost of illness was € 13,622 
for Golimumab, € 12,803 Adalimumab, € 11,924 Etanercept, € 11,830 Tocilizumab, 
€ 11,201 Infliximab, € 10,943 Abatacept. Dose escalation was associated with a higher 
expenditure for biologic (€ 12,248 VS € 11,232, p= 0.023) and no difference on other 
costs (€ 464 VS € 566, p= 0.349). ConClusions: Among patients with RA, Abatacept 
was associated to a lower cost of illness and hospitalization ratio, due to a low dose 
escalation rate.
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objeCtives: Recently biological agents with a mechanism of action targeting the 
pathogenesis of rheumatoid arthritis (RA) have emerged as an important treatment. 
Especially, as anti-TNF (anti-tumor necrosis factor antagonist) drugs are effective 
objeCtives: The Work Limitations Questionnaire (WLQ) measures the degree to 
which employed individuals are experiencing health-related limitations at work, 
as well as health-related productivity loss. The PALACE 1 study compared the 
efficacy and safety of apremilast (APR) with placebo in patients with active pso-
riatic arthritis (PsA) despite prior or concurrent conventional disease-modifying 
antirheumatic drugs (DMARDs) and/or prior biologics. The objective of the current 
analysis was to assess the effect of APR on the work productivity of employed 
patients in PALACE 1. Methods: Patients were randomized (1: 1: 1) to receive 
placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30). Treatment efficacy 
was assessed at Week 16 based on the intent-to-treat population. Employed 
patients completed the WLQ at baseline and Week 16. Work limitations were cat-
egorized into 4 domains, which were then used to calculate the WLQ index: physi-
cal demands (PDS), mental demands (MDS), time management demands (TMS), 
and output demands (ODS). Improvement in the WLQ index, and its 4 domains, 
is represented by a negative change from baseline. Improvement in work pro-
ductivity is represented by a positive improvement in percentage of productivity 
loss. Results: 504 patients were randomized (mean age: 50.4 years; male: 49.4%). 
Of these, 261 who were employed and completed at least 1 component of the 
WLQ were analyzed. At Week 16, APR20 and APR30, vs. placebo, were associated 
with a greater mean change from baseline in PDS (-5.58 and -6.24 vs. -2.14), MDS 
(-2.22 and -5.18 vs. 1.15), TMS (-4.03 and -8.76 vs. -4.25), and ODS (-5.92 and -10.3 
vs. -1.34), resulting in a greater mean improvement in the WLQ index (-0.01 and 
-0.03 vs. 0.00), which corresponds to a higher median percent improvement of 
productivity loss (18.9% and 24.7% vs. -3.7%). ConClusions: APR20 and APR30 
increased work productivity among patients with active PsA.
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objeCtives: To compare the relative efficacy of ustekinumab to alternative thera-
pies in anti-TNF treatment-naïve adult patients with active PsA, while adjusting 
for the variability in placebo response rates across trials. Methods: A Bayesian 
network meta-analysis (NMA) was performed to compare ustekinumab with 
adalimumab, golimumab, etanercept, certolizumab pegol and infliximab. Four out-
comes (PASI75, PASI90, PSARC, ACR20) were analysed after 12-16 and 24 weeks. 
The NMA was conducted using a meta-regression model, with the trial-specific 
estimated baseline risk included as a covariate (Dias et al., 2013). A sceptical prior 
was used for this covariate. Both fixed (FE) and random effects models were con-
sidered. Results: Nine placebo-controlled trials were identified for inclusion in 
the NMA based on systematic literature review, including 2 ustekinumab trials. The 
placebo response rates varied significantly across trials, with ustekinumab trials 
having generally higher values. The median value of the meta-regression coefficient 
ranged between -0.02 and -1.69 (P [coef< 0] between 50% and 95%) over the different 
scenarios and models, suggesting an interaction effect between baseline risk and 
treatment effects. At week 24 using the FE, the probability for ustekinumab 45mg 
and 90mg to be more effective than the comparators based on the PASI75 ranged 
from 87% (etanercept) to 46% (golimumab 100mg) and from 88% (etanercept) to 50% 
(golimumab 100mg), respectively. The variability around the point estimates was 
however large. ConClusions: This analysis indicates baseline risk in PsA-trials 
to be a treatment effect modifier. Any NMA not correcting for baseline risk might 
generate biased results. After adjusting for differences in baseline risk between the 
trials, ustekinumab indicates comparable efficacy to alternative therapies, however 
with high uncertainty around the point estimates.
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objeCtives: To compare the disease status and outcomes of patients with PsA 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A 
multi-country, multi-center medical chart-review study of AS patients was con-
ducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-
identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30yrs) and patient 
volume (incl. > 5PsA biologic patients/month) and recruited from a large panel to 
be geographically representative in each country. Eligible patient charts (≥ 3) were 
randomly selected from a sample of prospective patients visiting each center/prac-
tice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status/outcomes. 
Patients on adalimumab/etanercept monotherapy were analyzed. Results: 249 
eligible PsA patient charts were abstracted; 120 on adalimumab (male: 58%, age: 
46.2yrs, average months on adalimumab: 23.9, 95% on first biologic) and 81 on 
etanercept (male: 51%, age: 47.6yrs, average months on etanercept: 22.7, 94% on 
first biologic). Top-3 comorbidites (adalimumab vs. etanercept) were obesity: 12% 
(range: 4% (France) -20% (Germany)) vs. 9% (range: 0% (France) -25% (UK)), dyslipi-
demia: 8% (range: 0% (Italy) -13% (UK)) vs. 16% (range: 0% (UK) -24% (Italy)) and 
anxiety/depression: 12% (range: 7% (UK) -22% (France)) vs. 6% (range: 0% (UK) -12% 
(Spain)). Among patients with available data, latest lab measures documented were 
(adalimumab vs. etanercept): ESR: 19.2mm/h (range: 16.0 (France) -23.6 (Italy)) vs. 
22.0mm/h (range: 13.0 (Germany) -30.1 (Italy)), CRP: 6.5mg/dl (range: 1.3 (Spain) 
-10.8 (UK)) vs. 13.7mg/dl (range: 6.7 (Germany) -24.0 (UK)), rheumatoid factor-
positive: 10% (range: 0% (UK/Spain) -19% (Germany)) vs. 17% (range: 7% (Spain) 
-50% (UK)), and anti-CPP-positive: 5% (range: 0% (France/Italy/Spain) -50% (UK)) 
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(UK) -4.8 (Spain)) vs. 3.2 (1.5 (Germany) -6.6 (Spain), VAS score: 3.8 (range: 3.0 (UK) 
-4.8 (Italy)) vs. 3.1 (range: 1.9 (Germany) -3.9 (Italy)). ConClusions: Among RA 
patients receiving adalimumab or etanercept monotherapy, disease severity was 
similar across the EU5, with patients in Spain and France having relatively lower, 
and patients in Italy, Germany, and UK having relatively higher burden and poorer 
treatment response. Factors influencing the observed patterns of geographic vari-
ation warrant further scrutiny to optimize therapeutic interventions and improve 
outcomes.
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indiRect coMPaRiSon
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1Symmetron Limited, Herts, UK, 2Symmetron Limited, Borehamwood, UK, 3F. Hoffmann-La Roche, 
Basel, Switzerland
objeCtives: We evaluated the effectiveness of traditional disease-modifying 
antirheumatic drugs (tDMARDs) and novel DMARDs, alone and in combination, 
in methotrexate- and biologic-naive adults with moderate to severe early rheu-
matoid arthritis (ERA; < 3-year duration). Methods: Literature review identified 
randomized controlled trials (RCTs) of tDMARDs and novel DMARDs reporting 
efficacy outcomes (American College of Rheumatology [ACR] 20/50/70/90 response 
and Disease Activity Score at 28 joints [DAS28] remission). Data were pooled using 
Bayesian network meta-analysis techniques. For ACR response, data were analyzed 
using a fixed-effects ordered probit model, which makes efficient use of ordered 
categorical data and guarantees coherent prediction of multinomial response prob-
abilities. For DAS28 remission, data were analyzed with a fixed-effects binomial 
logit model. Sensitivity analyses tested the effects of grouping treatments by class 
and broadening/narrowing inclusion criteria. Results: Results from a synthesis 
of 16 RCTs of tDMARDs (methotrexate, sulfasalazine, hydroxychloroquine) and 
novel DMARDs (biologics [abatacept, adalimumab, etanercept, infliximab, goli-
mumab, tocilizumab] and tofacitinib) indicated that biologics+methotrexate, triple 
tDMARDs, and tocilizumab and tofacitinib monotherapy significantly increased 
response across all ACR categories versus methotrexate. ACR response probabilities 
for biologics+methotrexate were not significantly different between agents. ACR 
response probabilities to novel DMARD monotherapy varied, trending toward higher 
values for tofacitinib and tocilizumab than etanercept or adalimumab. In studies 
reporting DAS28 remission, treatment with tofacitinib or biologics±methotrexate, 
except adalimumab alone, improved remission likelihood versus methotrexate. 
Tocilizumab±methotrexate generated the highest probability of remission among 
biologics and was significantly more effective than other biologics±methotrexate 
and tofacitinib. Results across outcomes were robust to alternative grouping of 
interventions and change in inclusion criteria. ConClusions: Based on ACR 
response, the expected efficacy of biologics+methotrexate, tofacitinib and tocili-
zumab monotherapy, and triple tDMARD therapy appeared higher than MTX in 
ERA. Tocilizumab±methotrexate was expected to have the highest probability 
of generating DAS28 remission and was significantly more effective than other 
biologics±methotrexate and tofacitinib.
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objeCtives: This study aims to provide estimates of EQ-5D as a function of Health 
Assessment Questionnaire – Disability Index (HAQ-DI) scores in patients with 
rheumatoid arthritis (RA) in Taiwan. Methods: Face-to-face patient interviews 
on a total of 140 patients aged between 30 and 70 years old were recruited at the 
rheumatology outpatient clinics of four hospitals located in northern, central and 
southern Taiwan during June 2013-May 2014. The severity distribution of patients 
was mild RA (Disease Activity Score [DAS 28] < 3.2) (N= 57), moderate RA (3.2□…
DAS< 5.1) (N= 44), and severe RA (DAS≥ a5.1) (N= 39). Socio-demographic and clinical 
information were collected, and the HAQ-DI and the EQ-5D questionnaires were 
completed. Generalized linear regression models were used to predict EQ-5D util-
ity values as functions of HAQ-DI scores, age, and gender. Results: Patient mean 
age was 50.8 years old (standard deviation [SD], 11.3 years); 81.4% of the patients 
were women and mean disease duration was 9.65 years (SD, 6.84 years). HAQ-DI 
< 0.5, 58%; 0.5□…HAQ-DI< 1.1, 16%; 1.1□…HAQ-DI< 1.6, 9%, 1.6□… HAQ-DI< 2.1, 12%; 
and HAQ-DI≥ a2.1, 4%. HAQ-DI and EQ-5D mean scores were 12.01 (SD, 7.8) and 0.67 
(SD, 0.34), respectively. The models were able to predict actual EQ-5D across the 
range of the HAQ DI. Age and gender were found to be significant determinants in 
estimating the utility functions. ConClusions: Utility values have very often not 
been assessed in the data collection process in a clinical trial. This study showed 
that HAQ-DI scores can be used to derive EQ-5D utility values for patients with RA 
in Taiwan to facilitate conducting a cost-utility analysis.
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objeCtives: Patient age is one of many potential risk factors for fracture nonunion. 
We evaluate impact of age on heal rate (HR) in patients with fresh fracture (≤ 90 
days old). Our hypothesis is that age is not a risk factor for nonunion if fractures 
are treated with LIPUS. Methods: A LIPUS device was approved in 1994 to acceler-
ate fresh fracture healing, though the FDA required a Post-Market Registry. Patient 
data were collected from October 1994 until October 1998 and were reviewed and 
for patients who do not respond to traditional disease modifying anti-rheumatic 
drugs (DMARDs). This study aimed to compare the efficacy of biological agents with 
traditional DMARDs for methotrexate (MTX) treatment failure patients. Methods: 
Four DMARDs (hydroxychloroquine, sulfasalazine, methotrexate, leflunomide) and 
five anti-TNF drugs (adalimumab, etanercept, golimumab, infliximab, certolizumab) 
were selected according to expert consensus. A systematic search of the published 
systematic reviews was performed including MEDLINE, EMBASE and Cochrane 
Library. Among the identified 52 systematic reviews, 3 systematic reviews were 
finally selected and updated to July 2013. Data extraction and methodological qual-
ity assessment using Cochrane Risk of Bias was performed in pairs. Comparative 
efficacy was analyzed using Baysian mixed treatment comparison (MTC). Results: 
A total of 85 trials from 7,938 citations were included. Nineteen trials were grouped 
as MTX failure patients (mean age: 52.9 years, mean of rheumatoid factor posi-
tive rate: 76.6%). Nine studies were included in the analysis of Health Assessment 
Questionnaire (HAQ). The best treatment was certolizumab combined with MTX (MD 
-0.40,95% CrI -0.95 to 0.13). For comparative effects on DAS 28-ESR < 2.6 (remission), 
4 trials were included in analysis. The best treatment was golimumab combined 
with MTX (OR 24.5, 95% CrI 3.51 to 99.52). For comparative effects on ACR 70, the best 
treatment was certolizumab combination with MTX (OR 10.46, 95% CrI 3.66 to 24.41) 
in 11 trials. ConClusions: In the MTX failure patients, certolizumab combination 
with MTX lowered HAQ score than MTX. The result of DAS 28- ESR< 2.6 (remission), 
golimumab combined with MTX was the most effective treatment. Certolizumab 
combined with MTX was best treatment for the ACR 70 response.
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QUality of life aSSeSSMentS in koRean PatientS With RheUMatoid 
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eQUivalence of the etaneRcePt bioSiMilaR hd203 and enbRel®  
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objeCtives: Quality of Life (QoL) is important for patients with RA and Enbrel® has 
demonstrated QoL benefits in this patient group. HD203 is an etanercept biosimilar, 
which reported pharmacokinetic bioequivalence to the reference product Enbrel® 
in a Phase I trial and, more recently, demonstrated equivalent efficacy and compa-
rable safety in a phase III randomized trial in Korean patients with RA. Assessing 
QoL was a secondary objective of the HERA study, the results of which are reported 
here. Methods: Patients (male or female aged ≥ 20 years) with active RA were 
randomized (1: 1) to 25 mg HD203 or Enbrel®, administered subcutaneously twice 
weekly with MTX for 48 weeks. QoL assessments (Short Form 36, SF-36; Functional 
Assessment of Chronic Illness Therapy-Fatigue, FACIT-F; EuroQol-5 dimension, 
EQ5D) were undertaken at weeks 24 and 48. Results: In total, 294 patients were 
randomized (147 to HD203; 147 to Enbrel®). There was no significant difference 
between groups on QoL assessments at baseline. QoL assessments were similar 
for HD203 and Enbrel® at week 24 and 48 overall. However, SF-36 Role Emotional 
and Bodily Pain subscales showed significant increase in favour of HD203 at week 
24 (p= 0.0252) and week 48 (p= 0.0243) respectively. No significant difference was 
observed between HD203 and Enbrel® for FACIT-F scores at week 24 or 48, except at 
week 48 for the Emotional Well-being domain, which was significantly improved 
with Enbrel® vs. HD203 (p= 0.0360). No significant differences between groups in 
EQ5D scores were observed at any time. ConClusions: Together with previous 
reports of equivalent pharmacokinetics and efficacy, and comparable safety, these 
data support the biosimilarity of HD203 vs. Enbrel®.
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objeCtives: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A 
multi-country, multi-center medical chart-review study of RA patients was con-
ducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-
identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 5 RA biologic patients/month) and recruited from a large panel to 
be geographically representative in each country. Eligible patient charts (≥ 3) were 
randomly selected from a sample of prospective patients visiting each center/prac-
tice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status/outcomes. 
Patients on adalimumab/etanercept monotherapy were analyzed. Results: 428 
eligible RA patient charts were abstracted; 152 on adalimumab (female: 68%, age: 
52.1yrs, average months on adalimumab: 22.8, 90% on first biologic) and 142 on 
etanercept (female: 70%, age: 50.5yrs, average months on etanercept: 24.6, 97% 
on first biologic). Among patients with available data, latest lab measures docu-
mented were (adalimumab vs. etanercept): ESR: 21.0mm/h (range: 16.1 (UK) -24.6 
(Germany)) vs. 23.4mm/h (range: 13.5 (France) -29.8 (Italy)), CRP: 9.9mg/dl (range: 
5.0 (Italy) -17.0 (Germany)) vs. 13.1mg/dl (range: 7.7 (France) -15.6 (Italy)), rheu-
matoid factor-positive: 81% (range: 68% (Germany) -86% (Spain)) vs. 85% (range: 
62% (Germany) -95% (Spain)), and anti-CPP-positive: 69% (range: 47% (Germany) 
-83% (France)) vs. 74% (range: 61% (Spain) -83% (France)). Latest disease severity 
measures documented were (adalimumab vs. etanercept): Swollen Joint Counts: 
2.7 (range: 2.2 (Spain) -3.5 (Germany)) vs. 2.6 (range: 0.7 (Spain) -6.3 (UK)), Tender 
Joint Counts were 3.9 (range: 3.2 (France) -5.1 (Germany)) vs. 3.7 (range: 1.5 (Spain) 
-7.1 (UK)), Health Assessment Questionnaire (HAQ) rating: 1.6 (range: 0.1 (Spain) 
-2.3 (Germany)) vs. 1.4 (0.3 (Spain) -2.5 (Germany), DAS28 score: 3.8 (range: 2.5 
